Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rgene Corporation
Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
Rgene Corporation has advanced three oncology drug candidates, including BLEX 404 (maitake mushroom extract), through Phase 2 clinical studies for multiple solid tumor indications. Early trials conducted at Memorial Sloan Kettering Cancer Center demonstrated safety and immunological activity. Rgene has entered licensing and co-development agreements for further development and commercialization, notably with ABVC BioPharma and OncoX. No pivotal/Phase 3 efficacy data are reported yet.[1][3]
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeImmunostimulantBiologic
- Industry
- Biotech
02
Partnerships
ABVC BioPharmaOncoX
Beyond the preview
Go deeper on Rgene Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rgene Corporation.